Medical News Podcast

Drs. Sarswat and Dasgupta discuss contemporary decision-making in treating transthyretin amyloidosis, comparing oral stabilizers with subcutaneous silencers and emphasizing earlier diagnosis, phenotype-driven therapy, and individual patient preferences. They highlight how neuropathy and autonomic dysfunction influence choice of mechanism, review practical considerations such as side-effect profile...

Drs. Wierda and O’Brien discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.

Drs. Sanossian and Saver highlight emerging evidence that routine dental care and oral hygiene may function as actionable, modifiable contributors to stroke prevention beyond traditional vascular risk factors. They also review CREST-2 data showing that carotid revascularization in asymptomatic high-grade carotid stenosis reduces stroke risk, but does not appear to confer additional cognitive benef...

Drs. Swigris and Humphries discuss how data-driven texture analysis (DTA) on HRCT enables precise, objective quantification of fibrotic burden in ILD, overcoming the limitations of semi-quantitative visual scoring and blunt physiologic measures. They further describe a complementary AI-based classifier that predicts histologic usual interstitial pneumonia (UIP) patterns from CT, enhancing prognost...

Drs. Mantia and Berg discuss HER2 as a biomarker in genitourinary cancers, focusing on testing strategies, prevalence, and the clinical implications of HER2 expression and ERBB2 mutations for patient management. They also review new data from ESMO 2025, highlighting the DISTINCT-1 trial and a HER2-targeted approach for high-risk upper tract genitourinary carcinoma.

New cardiovascular data suggest pulsed field ablation may challenge antiarrhythmic drugs as first-line therapy for persistent atrial fibrillation, while real-world evidence positions apixaban as the preferred DOAC for younger patients with nonvalvular AF due to superior safety and effectiveness. Additional findings from the SENIOR-RITA trial indicate that routine invasive management may not benefi...

Daraxonrasib, a first-in-class oral RAS inhibitor, nearly doubled overall survival versus chemotherapy in previously treated metastatic pancreatic cancer, representing a potentially landmark advance in a historically difficult-to-treat disease. The antibody-drug conjugate datopotamab deruxtecan significantly improved progression-free and overall survival over chemotherapy in first-line triple-nega...

Drs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function chec...

Shingles vaccination in adults with established cardiovascular disease was associated with dramatic reductions in heart attack, stroke, and mortality in a large real-world analysis, supporting its role as a cardiovascular risk-reduction tool beyond infection prevention. The VESALIUS-CV trial found evolocumab significantly reduced major cardiovascular events in high-risk diabetic patients without k...

Drs. Yiu and Emami review key themes from the 49th Annual Macula Society Meeting, emphasizing a shift toward earlier diagnosis and intervention, longer-acting therapies, and increasing reliance on advanced imaging biomarkers and AI. They also look at new and existing data on a range of emerging treatment options for both neovascular and atrophic macular conditions.

Drs. Kuruvilla and Chandwani discuss migraine as a key women’s health issue driven largely by estrogen fluctuations across a woman’s lifespan, influencing CGRP, serotonin, sleep, and comorbid pain conditions from menstruation through perimenopause and menopause. These experts emphasize individualized, interdisciplinary care that combines CGRP-targeted preventives, hormonal strategies, integrative...

A trial found that discontinuing beta-blockers in stable post-MI patients without heart failure was noninferior to continuing them, suggesting long-term use may be unnecessary. Second, the 2026 ACC/AHA lipid guideline promotes earlier, personalized intervention using the PREVENT risk calculator and expanded biomarkers to reduce lifetime cardiovascular risk. Finally, a JAMA study found thiazide diu...

Drs. Swigris and Humphries discuss how AI-driven, quantitatively trained algorithms can standardize the interpretation of high-resolution computed tomography (HRCT) in ILD by reducing inter- and intra-reader variability and improving fibrosis extent assessment. They contrast traditional visually based radiology with supervised machine learning approaches, including models trained on biopsy-confirm...

A randomized trial in the New England Journal of Medicine found prehospital whole blood transfusion did not improve 30-day mortality over standard component therapy in traumatic hemorrhage, supporting current transfusion protocols. A large population-based study showed patients with positive fecal occult blood tests who did not complete follow-up colonoscopy had significantly higher colorectal can...

Drs. Sanossian and Saver review new evidence supporting intensified antithrombotic strategies to reduce recurrent ischemic stroke in high-risk, noncardioembolic patients without increasing intracranial hemorrhage. They place this within a comprehensive, multimodal secondary prevention framework that integrates pharmacologic therapy with aggressive risk factor modification (lipids, blood pressure,...

Drs. O’Brien and Wierda discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.

Drs. Dougherty and Ailani discuss the 2025 International Headache Society guidelines indicating that neuromodulation is an effective, non-invasive option for both acute and preventive migraine treatment. They stress that it works best as part of a personalized, multimodal plan alongside medications, behavioral therapies, and lifestyle changes.

Drs. Maron and Rowin provide an overview of hypertrophic cardiomyopathy, explaining how it is diagnosed by heart imaging and classified into obstructive and non-obstructive forms. They highlight that obstruction is a major cause of symptoms and stress the importance of carefully assessing patients’ day-to-day limitations to guide treatment decisions.

Drs. Petri and Woolfson discuss a simple risk score using autoantibodies, complement, and demographics to predict which SLE patients are most likely to develop proteinuria and lupus nephritis. They also highlight evidence showing that earlier kidney biopsies at lower proteinuria levels, especially in patients with low complement, can detect serious disease sooner and improve outcomes.

This week's podcast covers three NEJM trials. First, apixaban showed over 50% less clinically relevant bleeding than rivaroxaban in acute venous thromboembolism patients, with similar efficacy. Second, romiplostim helped 84% of patients on oxaliplatin-based chemotherapy avoid dose modifications due to thrombocytopenia, versus 36% with placebo. Third, inhaled treprostinil slowed lung function decli...

Drs. Isaacs and Traina discuss DESTINY-Breast09, where first‑line T‑DXd + pertuzumab clearly outperforms the CLEOPATRA regimen in progression-free survival for metastatic HER2+ breast cancer. They focus on the dilemma of when to use T‑DXd: earlier, for maximal efficacy, or later, to protect quality of life and manage ILD and cardiac risks.

The WISDOM trial found risk-based breast cancer screening — using genetic and polygenic risk scores — is non-inferior to annual mammography, enabling more intensive surveillance for high-risk women while reducing unnecessary imaging for low-risk individuals. Among hypertensive adults, prediabetes combined with elevated cardiac biomarkers significantly increases heart failure risk, suggesting combi...

Drs. Cytryn, Foote, and Thummalapalli review evolving HER2-targeted treatment strategies for upper GI, biliary, and colorectal cancers, emphasizing challenges with disease heterogeneity and treatment sequencing. They also highlight the importance of HER2 reassessment after progression and advancing diagnostic approaches.

Three studies highlight new findings: A phase 3 trial showed obinutuzumab significantly improved lupus responses versus placebo in active SLE patients on standard therapy. A trial of finerenone in type 1 diabetes with chronic kidney disease demonstrated meaningful reductions in albuminuria compared to placebo, suggesting a new renal-protective option. Finally, paired pediatric trials found that ad...

Drs. Isaacs and Traina review how HER2CLIMB‑05 and PATINA challenge the old CLEOPATRA‑based approach by showing that adding tucatinib or palbociclib to maintenance therapy can extend progression‑free survival in metastatic HER2+ breast cancer. They stress tailoring maintenance regimens to each patient’s hormone receptor status, CNS risk, and tolerance for side effects.